Functional Precision Oncology

Transforming how cancer therapy is chosen.

SynRx™ is a proprietary platform that measures how a patient’s living tumor cells respond to approved and emerging cancer therapies, before treatment begins. By observing real cellular effects rather than relying on genetic prediction alone, SynRx™ helps physicians design treatment plans that are targeted and evidence‑based.

Functional Precision Oncology

SynRx™ is a proprietary platform that measures how a patient’s living tumor cells respond to approved and emerging cancer therapies—before treatment begins. By observing real cellular effects rather than relying on genetic prediction alone, SynRx™ helps physicians design treatment plans that are targeted and evidence‑based.

Transformin​​g how cancer therapy is chosen.

Why SynRx™ is Different

Direct Functional Evidence

Tests living tumor cells to observe actual cell death, growth arrest, and resistance, rather than inferring response from genetics alone.

Combination Insight

Interrogates single agents and rational combinations to surface potential synergy or antagonism for an individual patient.

Clear Response Mapping

Ranks therapies by observed effect and presents results as an interpretable SynRx™ Response Profile for clinician decision‑making.

Adaptive Over Time

Supports re‑testing when the disease evolves, aligning therapy with the tumor’s changing behavior.

How SynRx™ Works

SynRx™ integrates cell biology, quantitative cytometry, and analytics to create a patient‑specific functional fingerprint.

  1. Cell Preparation. A viable tumor specimen is processed under optimized conditions to preserve representative cancer cell populations.
  2. Therapeutic Challenge. Cells are exposed to a structured panel of chemotherapies, targeted agents, immune‑modulating drugs, and select combinations at clinically relevant ranges.
  3. Cytometric Analysis.  multi-parametric assays quantify tumor cell response to traditional chemotherapeutics, targeted kinase inhibitors, immunotherapuetics, and andiangiogenics.
  4. Response Mapping. The system integrates findings into a SynRx™ Response Profile, ranking therapies by observed effect and flagging resistance.
Deliverables
  • Ranked list of therapies and combinations by functional activity
  • Visual response curves and effect categories (active / limited / resistant)
  • Method notes and interpretation guidance
Turnaround & Logistics
  • Requires a fresh, viable specimen with adequate cellularity
  • Testing panel tailored to clinical context and prior therapies
  • Results delivered in a clear, clinician‑readable report

Clinical Value

For Physicians

  • Evidence‑based support for regimen selection in complex or refractory cases
  • Clarity on non‑responsive options to reduce unnecessary toxicity
  • Signals for combination strategies and sequencing
  • Framework to reassess when disease biology shifts

For Patients & Families

  • Personalized insight grounded in the behavior of your own cancer cells
  • Fewer trial‑and‑error cycles and reduced exposure to ineffective drug
  • Transparent reports that your care team can discuss with you

Frequently Asked Questions

Is SynRx™ the same as genetic testing?

No. Genetic and molecular tests identify mutations that may hint at sensitivity or resistance. SynRx™ observes functional response directly, how living tumor cells react to therapies, so the methods are complementary.

Can every patient sample be tested?

Testing requires a fresh, viable specimen with adequate cellularity. Yield and tumor heterogeneity may affect feasibility or scope.

Are all drugs and combinations included?

Panels reflect clinical context and practicality. Not every agent can be tested, and clinical judgment remains essential.

Does SynRx™ replace oncologist expertise?

No. SynRx™ is a decision‑support tool. Results are interpreted by clinicians within each patient’s broader medical picture.